GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Cash, Cash Equivalents, Marketable Securities

Abbisko Cayman (HKSE:02256) Cash, Cash Equivalents, Marketable Securities : HK$2,092.0 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Cash, Cash Equivalents, Marketable Securities?

Abbisko Cayman's quarterly cash, cash equivalents, marketable securities increased from Dec. 2023 (HK$2,149.25 Mil) to Jun. 2024 (HK$2,286.30 Mil) but then stayed the same from Jun. 2024 (HK$2,286.30 Mil) to Dec. 2024 (HK$2,092.02 Mil).

Abbisko Cayman's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (HK$2,627.21 Mil) to Dec. 2023 (HK$2,149.25 Mil) and declined from Dec. 2023 (HK$2,149.25 Mil) to Dec. 2024 (HK$2,092.02 Mil).


Abbisko Cayman Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Abbisko Cayman's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Cash, Cash Equivalents, Marketable Securities Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 732.33 3,116.90 2,627.21 2,149.25 2,092.02

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,627.21 2,406.89 2,149.25 2,286.30 2,092.02

Abbisko Cayman Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Abbisko Cayman  (HKSE:02256) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Abbisko Cayman Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has only one business segment which is the development of medicines.
Executives
Xu Yao-chang 2101 Beneficial owner
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines